CML Naples Fellows Day 2014

On May 5-6, the 6th Naples Fellows Day is held in Naples, Italy. Focussing on current treatment paradigms and future perspectives, this meeting allows young hematologists to exchange knowledge with leading experts in chronic myeloid leukemia. Deadline to register is April 11, 2014. ▶ Link to registration

Impact of bureaucracy on patient care in clinical research

Over the past decade, cancer research bureaucracy has become a major burden for the initiation of clinical trials. Just recently, a critical paper on this issue has been published in the Journal of Clinical Oncology. Herein, David Steensma and Hagop Kantarjian rise the question if these increasing regulatory requirements are still proportional to the benefit for patient safety and trial quality. ▶ JCO. 2014;32(5):376-8.

Publications from the Network (selected)

Acute lymphoblastic leukemia

- Eefting M et al. Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transplant. 2014 Feb;49(2):287-91.

Acute myeloid leukemia

- Fasan A et al. Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases. Haematologica. 2014 Feb;99(2):e20-1.


Chronic myeloid leukemia
- Hehlmann R et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014 Feb 10;32(5):415-23.

Chronic lymphocytic leukemia

Myelodysplastic syndromes

Myeloproliferative neoplasms


Stem cell transplantation


Miscellaneous


**New trials in the ELTR**

**CINC424A2104 (HARMONY)** A Phase Ib, Open-label, Multi-center, Two-arm, Dose-finding Study to Assess Safety and Efficacy of the Oral Combination or INC424 (INC424) and BKM120 in Patients With Primary Myelofibrosis (PMF), Postpolycythemia Vera-myelofibrosis (PPV-MF), or Post-essential Thrombocythemia-myelofibrosis (PET-MF)